|Previous Section||Index||Home Page|
Mr. Bradshaw: The residual value guarantee in relation to the Norton NHS Treatment Centre (GC4 North Oxford), procured through Wave 1 of the independent sector treatment centre (ISTC) programme, is £15.1 million. The contract runs until 31 December 2010. The assets at Horton to be acquired upon payment of the residual value include the ISTC building.
Norman Lamb: To ask the Secretary of State for Health what (a) targets and (b) guidelines have been set for trusts to deal with delayed discharge; and what penalty is paid by trusts for delayed discharge of (i) patients with mental health problems and (ii) other patients. 
Mr. Ivan Lewis: The NHS Plan: A plan for investmenta plan for reform (Cm 48 18-1) contained the commitment to reduce widespread delayed discharges by 2004. Councils and their national health service partners have made significant progress in reducing delays in hospital. Between September 2001 and December 2007 the number of people over the age of 75 delayed in hospital reduced from 5,673 to 1,594, a reduction of 72 per cent. and total delays for the same period were reduced from 7,065 to 2,090, a reduction of 70 per cent. A copy of the NHS Plan is available in the Library.
Guidance on the implementation of the Community Care (Delayed Discharges etc) Act 2003, including the definition of, and procedures for notifying, delayed discharges was issued on 24 September 2003 as HSC 2003/009 and LAC (2003) 21. This guidance is still current and has not been amended.
Daniel Kawczynski: To ask the Secretary of State for Health if he will bring forward legislative proposals to end the practice of charging fees to patients with blue disability badges at hospital car parks in England. 
Mr. Bradshaw: Charging for car parking is a matter for individual national health service bodies. If they did not charge for car parking then funds for the maintenance and operation of the car park would have to be diverted from patient services. The Department has issued guidance advising NHS bodies to consider the needs of disabled users when planning their car parks and to offer concessions or free parking to those who have to use their car parks regularly, which may include some blue disability badge holders. We have no plans to change these arrangements.
Sir Nicholas Winterton: To ask the Secretary of State for Health how the cost-effectiveness of pulmonary arterial hypertension drugs is determined; and what assessments were made by the National Institute for Health and Clinical Excellence of potential quality of life improvements offered by such drugs. 
Dawn Primarolo: The National Institute for Health and Clinical Excellence (NICE) draws on a number of different sources of information to appraise the clinical and cost-effectiveness of drugs assessed through its multiple technology appraisals (MTA) process. The different sources of information are set out in more detail in NICE'S Guide to the methods of technology appraisal which can be found at:
NICE'S appraisal of drugs for the treatment of pulmonary arterial hypertension is currently out for consultation and the appraisal consultation document sets out in detail the evidence for NICE'S draft recommendations.
|Total active users||Monthly registered accounts|
|(1) The number of users registering for the service each month is a calculation based on: (current month active users) minus (last month active users).|
Jeff Ennis: To ask the Secretary of State for Health whether National Institute for Health and Clinical Excellence guidance on supportive and palliative care has been implemented in Barnsley East and Mexborough constituency. 
Mr. Ivan Lewis: It is for individual primary care trusts (PCTs), including Barnsley PCT, within the national health service to commission services for their resident population, including end of life care, based on assessments of local needs and priorities. The NHS has been required to set out action plans to achieve compliance with the National Institute for Health and Clinical Excellence recommendations on supportive and palliative care. Implementation is being monitored by strategic health authorities (SHAs).
Dawn Primarolo: Reports of suspected adverse drug reactions (ADRs) are collected by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission for Human Medicines (CHM) through the spontaneous reporting scheme; the Yellow Card Scheme. Approximately 20,000 reports of ADRs are reported to the MHRA/CHM through this scheme each year. The scheme collects ADR reports from across the whole United Kingdom and includes all medicines, including those from prescriptions, over-the-counter or general retail sales. Reports are also received for herbal medicines and other unlicensed medicines.
|Year received by MHRA||Number of spontaneous UK suspected ADR reports received||Number of spontaneous UK suspected ADR reports received with a fatal outcome||Number of spontaneous UK suspected ADR reports received which resulted in or prolonged hospitalisation|
|Next Section||Index||Home Page|